Home / Recalls / Chembio Diagnostics, Inc / Z-2807-2020

Z-2807-2020 Class II Terminated

Recalled by Chembio Diagnostics, Inc — Medford, NY

FDA device recall Z-2807-2020 was initiated by Chembio Diagnostics, Inc on Jun 18, 2020 and is designated Class II. Reason for recall: FDA revocation of the Emergency Use Authorization due to performance issues The recall status is terminated (terminated Aug 11, 2021). Affected quantity: 7,674 kits (153,480 devices).

Recall details

Product Type: Devices
Report Date: Aug 26, 2020
Initiation Date: Jun 18, 2020
Termination Date: Aug 11, 2021
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 7,674 kits (153,480 devices)

Product description

Chembio DPP COVID-19 IgM/IgG System- Rrapid immunochromatographic test for the qualitative detection and differentiation of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to SARS-CoV-2 in fingerstick whole blood, venous whole blood, serum, or plasma (lithium heparin or EDTA. Model Number: 65-9569-0

Reason for recall

FDA revocation of the Emergency Use Authorization due to performance issues

Distribution pattern

Nationwide

Code information

Lot Numbers: CV041020/A CV041520 CV040220/A1 CV042420 CV042920 CV040320/A2 CV050120

Source

Dataset: openFDA device recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for Z-2807-2020
openFDA file date: Nov 10, 2026
Loaded by RegDataLab: Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.